Cerity Partners LLC raised its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 58.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 694,417 shares of the company's stock after buying an additional 256,933 shares during the quarter. Cerity Partners LLC owned about 0.47% of Adaptive Biotechnologies worth $3,555,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. JTC Employer Solutions Trustee Ltd acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Adaptive Biotechnologies during the third quarter worth about $34,000. MQS Management LLC acquired a new position in shares of Adaptive Biotechnologies in the second quarter valued at approximately $36,000. Rothschild Investment LLC acquired a new position in shares of Adaptive Biotechnologies in the second quarter valued at approximately $36,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Adaptive Biotechnologies by 769.6% during the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company's stock valued at $48,000 after buying an additional 11,852 shares during the period. Hedge funds and other institutional investors own 99.17% of the company's stock.
Analysts Set New Price Targets
ADPT has been the subject of several recent analyst reports. Piper Sandler lifted their target price on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. BTIG Research lifted their price objective on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. increased their target price on Adaptive Biotechnologies from $5.00 to $6.00 and gave the stock an "overweight" rating in a research report on Friday, August 2nd.
Check Out Our Latest Analysis on Adaptive Biotechnologies
Adaptive Biotechnologies Price Performance
NASDAQ:ADPT traded up $0.21 during trading hours on Friday, reaching $5.94. 660,525 shares of the company were exchanged, compared to its average volume of 1,422,081. Adaptive Biotechnologies Co. has a 52-week low of $2.28 and a 52-week high of $6.70. The stock has a 50 day simple moving average of $5.07 and a 200 day simple moving average of $4.38. The firm has a market cap of $876.63 million, a price-to-earnings ratio of -4.43 and a beta of 1.45.
Adaptive Biotechnologies Company Profile
(
Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Further Reading
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
